Peptide Library

Human study PLS-00251

Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction

Other design · Not reported participants enrolled

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarctionregistry entry · NCT07586865 (NOT_YET_RECRUITING, no results posted, planned enrollment 189)

Design and participants

Design
Other design
Population
Patients with acute myocardial infarction, including anterior wall, left ventricular and ST-segment elevation myocardial infarction. Eligibility details are not in the record.
Conditions
Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall, Acute Myocardial Infarction With ST Elevation, Acute Myocardial Infarction of Left Ventricle, Acute Myocardial Infarction With ST Segment Elevation
Planned enrollment (registry)
189
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • NL005 (recombinant human thymosin beta 4) (intervention) · thymosin-beta-4 · Recombinant Human Thymosin Beta 4 Injection (NL005) · injection (specific route not stated) · Not reported assigned
  • Placebo (comparator) · Placebo · placebo · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • other: The registration has status not yet recruiting and has_results false, so no outcome data exist to appraise.
  • selective reporting: The record lists no registered primary or secondary outcomes, so outcome selection cannot be checked.
  • inadequate randomization: The record lists placebo and NL005 arms but does not state whether or how participants are randomized or blinded.
  • inappropriate population: Participants have acute myocardial infarction, which does not match the dry eye claim population.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Where each value comes from

  • arms: NCT NCT07586865, registry (interventions field) · extracted by AI (automated, not verified by a person)
  • design: NCT NCT07586865, registry (phases, study_type and interventions fields) · extracted by AI (automated, not verified by a person)
  • limitations: NCT NCT07586865, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
  • participants: NCT NCT07586865, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
  • population: NCT NCT07586865, registry (conditions field) · extracted by AI (automated, not verified by a person)

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).